PRP4K is a HER2-regulated modifier of taxane sensitivity
The taxanes are used alone or in combination with anthracyclines or platinum drugs to treat breast and ovarian cancer, respectively. Taxanes target microtubules in cancer cells and modifiers of taxane sensitivity have been identified in vitro, including drug efflux and mitotic checkpoint proteins. H...
Main Authors: | Corkery, Dale P, Le Page, Cécile, Meunier, Liliane, Provencher, Diane, Mes-Masson, Anne-Marie, Dellaire, Graham |
---|---|
Format: | Online |
Language: | English |
Published: |
Taylor & Francis
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612451/ |
Similar Items
-
Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies
by: Le Page, Cécile, et al.
Published: (2010) -
Connecting the speckles: Splicing kinases and their role in tumorigenesis and treatment response
by: Corkery, Dale P, et al.
Published: (2015) -
Subtype Specific Elevated Expression of Hyaluronidase-1 (HYAL-1) in Epithelial Ovarian Cancer
by: Yoffou, Paule Héléna, et al.
Published: (2011) -
Low expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosis
by: Tsofack, Serges P, et al.
Published: (2013) -
BTN3A2 Expression in Epithelial Ovarian Cancer Is Associated with Higher Tumor Infiltrating T Cells and a Better Prognosis
by: Le Page, Cécile, et al.
Published: (2012)